{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:14:36Z","timestamp":1779354876072,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:00:00Z","timestamp":1469145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["SpringerPlus"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40064-016-2819-8","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T02:32:51Z","timestamp":1469154771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis"],"prefix":"10.1186","volume":"5","author":[{"given":"Kashif","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"issue":"4","key":"2819_CR1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","volume":"163","author":"B Aksoy","year":"2010","unstructured":"Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N (2010) The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 163(4):719\u2013725","journal-title":"Br J Dermatol"},{"issue":"5 Suppl","key":"2819_CR2","first-page":"26","volume":"86","author":"HE Baldwin","year":"2010","unstructured":"Baldwin HE (2010) A community-based study of the effectiveness of doxycycline 40\u00a0mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis 86(5 Suppl):26\u201336","journal-title":"Cutis"},{"issue":"Suppl. 3","key":"2819_CR3","first-page":"10","volume":"52","author":"K Beutner","year":"2005","unstructured":"Beutner K, Calverese B (2005) A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1\u00a0% as compared to metronidazole gel vehicle and metronidazole cream 1\u00a0% in the treatment of rosacea. J Am Acad Dermatol 52(Suppl. 3):10","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2819_CR4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/000155599750009906","volume":"79","author":"R Bjerke","year":"1999","unstructured":"Bjerke R, Fyrand O, Graupe K (1999) Double-blind comparison of azelaic acid 20\u00a0% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 79(6):456\u2013459","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2819_CR5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/13548506.2013.841968","volume":"19","author":"D Bohm","year":"2014","unstructured":"Bohm D, Schwanitz P, Stock GS, Schmid-Ott G, Schulz W (2014) Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med 19(5):586\u2013591","journal-title":"Psychol Health Med"},{"issue":"11","key":"2819_CR7","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.12121","volume":"27","author":"B Cribier","year":"2013","unstructured":"Cribier B (2013) Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol 27(11):1336\u20131343","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2819_CR8","first-page":"38","volume":"34","author":"B Culp","year":"2009","unstructured":"Culp B, Scheinfeld N (2009) Rosacea: a review. P T 34(1):38\u201345","journal-title":"P T"},{"issue":"5","key":"2819_CR9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1067\/mjd.2001.116219","volume":"45","author":"MV Dahl","year":"2001","unstructured":"Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD (2001) Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 45(5):723\u2013730","journal-title":"J Am Acad Dermatol"},{"issue":"3 Suppl","key":"2819_CR10","first-page":"1","volume":"91","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D (2013a) An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 91(3 Suppl):1\u20138","journal-title":"Cutis"},{"issue":"6","key":"2819_CR11","first-page":"277","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E et al (2013b) Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 92(6):277\u2013284","journal-title":"Cutis"},{"issue":"6","key":"2819_CR12","first-page":"306","volume":"92","author":"ZD Draelos","year":"2013","unstructured":"Draelos ZD, Elewski B, Staedtler G, Havlickova B (2013) Azelaic acid foam 15\u00a0% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis 92(6):306\u2013317","journal-title":"Cutis"},{"issue":"5","key":"2819_CR13","first-page":"AB59","volume":"72","author":"Z Draelos","year":"2015","unstructured":"Draelos Z, Elewski B, Harper J, Sand M, Staedtler G (2015) Randomized, phase III, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12\u00a0weeks of twice-daily azelaic acid foam, 15\u00a0% in papulopustular rosacea. Journal of the American Academy of Dermatology 72(5):AB59","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"2819_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","volume":"139","author":"BE Elewski","year":"2003","unstructured":"Elewski BE, Fleischer AB Jr, Pariser DM (2003) A comparison of 15\u00a0% azelaic acid gel and 0.75\u00a0% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 139(11):1444\u20131450","journal-title":"Arch Dermatol"},{"issue":"2","key":"2819_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A et al (2011) Rosacea\u2014global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 25(2):188\u2013200","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2819_CR16","unstructured":"FDA (2014) SOOLANTRA\u2122 (ivermectin) cream, 1\u00a0% for topical use. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206255lbl.pdf"},{"issue":"6","key":"2819_CR17","first-page":"641","volume":"6","author":"JF Fowler Jr","year":"2007","unstructured":"Fowler JF Jr (2007a) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1\u00a0% in the treatment of rosacea. J Drugs Dermatol 6(6):641\u2013645","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2819_CR18","first-page":"641","volume":"6","author":"JF Fowler Jr","year":"2007","unstructured":"Fowler JF Jr (2007b) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1\u00a0% in the treatment of rosacea. J Drugs Dermatol 6(6):641\u2013645","journal-title":"J Drugs Dermatol"},{"key":"2819_CR19","unstructured":"Galderma (2006) A randomized, six-arm, dose-ranging, multi-center, investigator-blind, placebo and active comparator controlled trial to select the dose and regimen of Ivermectin (CD5024) according to the dose-response relationship. RD.03.SRE.40027 CSR"},{"key":"2819_CR20","unstructured":"Galderma (2014) CD5024 1\u00a0% cream versus metronidazole 0.75% cream in papulopustular rosacea (PPR) study (ATTRACT). RD.03.SRE.40173 CSR"},{"key":"2819_CR21","unstructured":"Galderma (2015a) Galderma receives FDA approval of novel treatment option for rosacea patients. http:\/\/www.galderma.com\/News\/articleType\/ArticleView\/articleId\/75\/Galderma-Receives-FDA-Approval-of-Novel-Treatment-Option-for-Rosacea-Patients . Accessed Feb 2015"},{"key":"2819_CR22","unstructured":"Galderma (2015b) Galderma announces positive outcome of European Decentralised Procedure for approval of Soolantra\u00ae (ivermectin) cream 10mg\/g for rosacea patients. http:\/\/www.galderma.com\/News\/articleType\/ArticleView\/articleId\/79\/Galderma-Announces-Positive-Outcome-of-European-Decentralised-Procedure-for-Approval-of-SOOLANTRA-ivermectin-Cream-10mgg-for-Rosacea-Patients . Accessed April 2015"},{"issue":"3","key":"2819_CR23","first-page":"316","volume":"13","author":"LS Gold","year":"2014","unstructured":"Gold LS, Kircik L, Fowler J, Tan J, Draelos Z (2014a) Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 13(3):316\u2013323","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"2819_CR24","first-page":"316","volume":"13","author":"LS Gold","year":"2014","unstructured":"Gold LS, Kircik L, Fowler J, Tan J, Draelos Z (2014b) Efficacy and safety of ivermectin 1\u00a0% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies (18171 study). J Drugs Dermatol 13(3):316\u2013323","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2819_CR25","first-page":"461","volume":"80","author":"C Goldgar","year":"2009","unstructured":"Goldgar C, Keahey DJ, Houchins J (2009) Treatment options for acne rosacea. Am Fam Physician 80(5):461\u2013468","journal-title":"Am Fam Physician"},{"issue":"6","key":"2819_CR26","first-page":"348","volume":"6","author":"TT Huynh","year":"2013","unstructured":"Huynh TT (2013) Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits 6(6):348\u2013354","journal-title":"Am Health Drug Benefits"},{"issue":"3","key":"2819_CR27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2230.2009.03427.x","volume":"35","author":"R Koca","year":"2010","unstructured":"Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS et al (2010) A comparison of metronidazole 1% cream and pimecrolimus 1\u00a0% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 35(3):251\u2013256","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl. 32","key":"2819_CR28","first-page":"S143","volume":"12","author":"R Koch","year":"1999","unstructured":"Koch R, Wilbrand G (1999) Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea. J Eur Acad Dermatol Venerol 12(Suppl. 32):S143\u2013S144","journal-title":"J Eur Acad Dermatol Venerol"},{"issue":"6","key":"2819_CR29","first-page":"685","volume":"13","author":"JJ Leyden","year":"2014","unstructured":"Leyden JJ (2014) Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol 13(6):685\u2013688","journal-title":"J Drugs Dermatol"},{"issue":"6 Pt 1","key":"2819_CR30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(99)70085-X","volume":"40","author":"S Maddin","year":"1999","unstructured":"Maddin S (1999) A comparison of topical azelaic acid 20\u00a0% cream and topical metronidazole 0.75\u00a0% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 40(6 Pt 1):961\u2013965","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2819_CR31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4155\/cli.11.50","volume":"1","author":"LE Maier","year":"2011","unstructured":"Maier LE (2011) Rosacea: advances in understanding pathogenesis and treatment. Clin Invest 1(5):739\u2013755","journal-title":"Clin Invest"},{"issue":"7733","key":"2819_CR32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(71)90376-X","volume":"2","author":"R Marks","year":"1971","unstructured":"Marks R, Ellis J (1971) Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 2(7733):1049\u20131052","journal-title":"Lancet"},{"issue":"4","key":"2819_CR33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264\u2013269","journal-title":"Ann Intern Med"},{"key":"2819_CR34","volume-title":"Face values: global perceptions survey report","author":"S Moore","year":"2015","unstructured":"Moore S (2015) Face values: global perceptions survey report. Galderma, Lausanne"},{"key":"2819_CR35","unstructured":"NCT00617903 (2013) Exploration of safety and efficacy of AzA 15% foam twice a day in rosacea"},{"key":"2819_CR36","unstructured":"NICE (2014) NICE DSU technical support document 2: a generalised modelling framework for pairwise and network meta-analysis of randomised controlled trials"},{"issue":"8","key":"2819_CR37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","volume":"352","author":"FC Powell","year":"2005","unstructured":"Powell FC (2005) Clinical practice. Rosacea. N Engl J Med 352(8):793\u2013803","journal-title":"N Engl J Med"},{"issue":"7971","key":"2819_CR38","first-page":"1211","volume":"1","author":"RJ Pye","year":"1976","unstructured":"Pye RJ, Burton JL (1976) Treatment of rosacea by metronidazole. Lancet 1(7971):1211\u20131212","journal-title":"Lancet"},{"key":"2819_CR6","unstructured":"SIGN Checklist (2015) SIGN checklist: critical appraisal of randomized controlled trials"},{"issue":"11","key":"2819_CR39","first-page":"1380","volume":"13","author":"GL Stein","year":"2014","unstructured":"Stein GL, Kircik L, Fowler J, Jackson JM, Tan J et al (2014) Long-term safety of ivermectin 1\u00a0% cream vs azelaic acid 15\u00a0% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 13(11):1380\u20131386","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"2819_CR40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J et al (2015a) Superiority of ivermectin 1% cream over metronidazole 0.75\u00a0% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 172(4):1103\u20131110","journal-title":"Br J Dermatol"},{"issue":"5","key":"2819_CR41","first-page":"AB6","volume":"72","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ruzicka T, Berth-Jones J, Peirone MH, Jacovella J (2015b) Comparative efficacy and safety of ivermectin cream 1\u00a0% and metronidazole cream 0.75\u00a0% in the treatment of papulopustular rosacea. J Am Acad Dermatol 72(5):AB6","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2819_CR42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10227-001-0144-4","volume":"6","author":"JK Tan","year":"2002","unstructured":"Tan JK, Girard C, Krol A, Murray HE, Papp KA et al (2002) Randomized placebo-controlled trial of metronidazole 1\u00a0% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 6(6):529\u2013534","journal-title":"J Cutan Med Surg."},{"key":"2819_CR43","unstructured":"The National Rosacea Society (2015) Skincare: sun protection and moisturizers. Available at: https:\/\/www.rosacea.org\/patients\/skincare\/moisturizer"},{"issue":"6","key":"2819_CR44","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","volume":"48","author":"D Thiboutot","year":"2003","unstructured":"Thiboutot D, Thieroff-Ekerdt R, Graupe K (2003) Efficacy and safety of azelaic acid (15\u00a0%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 48(6):836\u2013845","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2819_CR45","first-page":"541","volume":"7","author":"DM Thiboutot","year":"2008","unstructured":"Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K (2008) Azelaic acid 15\u00a0% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 7(6):541\u2013546","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2819_CR46","first-page":"357","volume":"75","author":"HM Torok","year":"2005","unstructured":"Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M et al (2005) Combination sodium sulfacetamide 10\u00a0% and sulfur 5\u00a0% cream with sunscreens versus metronidazole 0.75\u00a0% cream for rosacea. Cutis 75(6):357\u2013363","journal-title":"Cutis"},{"key":"2819_CR47","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z (2011) Interventions for rosacea. Cochrane Database Syst Rev (3):CD003262","DOI":"10.1002\/14651858.CD003262.pub4"},{"key":"2819_CR48","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L (2015) Interventions for rosacea. Cochrane Database Syst Rev 4:CD003262","DOI":"10.1002\/14651858.CD003262.pub5"},{"issue":"1","key":"2819_CR49","first-page":"73","volume":"79","author":"JE Wolf Jr","year":"2007","unstructured":"Wolf JE Jr, Del Rosso JQ (2007) The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 79(1):73\u201380","journal-title":"Cutis"},{"issue":"4 Suppl","key":"2819_CR50","first-page":"3","volume":"77","author":"JE Wolf Jr","year":"2006","unstructured":"Wolf JE Jr, Kerrouche N, Arsonnaud S (2006) Efficacy and safety of once-daily metronidazole 1\u00a0% gel compared with twice-daily azelaic acid 15\u00a0% gel in the treatment of rosacea. Cutis 77(4 Suppl):3\u201311","journal-title":"Cutis"}],"container-title":["SpringerPlus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40064-016-2819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40064-016-2819-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40064-016-2819-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T01:51:12Z","timestamp":1589680272000},"score":1,"resource":{"primary":{"URL":"http:\/\/springerplus.springeropen.com\/articles\/10.1186\/s40064-016-2819-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2819"],"URL":"https:\/\/doi.org\/10.1186\/s40064-016-2819-8","relation":{},"ISSN":["2193-1801"],"issn-type":[{"value":"2193-1801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]},"article-number":"1151"}}